Skip to content

Premedication to Reduce Discomfort With Screening Mammography

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00382083
Enrollment
Unknown
Registered
2006-09-28
Start date
2006-03-31
Completion date
2006-06-30
Last updated
2006-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Pain

Keywords

Mammogram, Pain, Discomfort, Breast, Pre-medication

Brief summary

This study will explore the effect of pre-medication with acetaminophen, ibuprofen, and topical lidocaine gel (Topicaine) on the perception of discomfort and overall satisfaction with the mammography experience. The research questions are: 1. What is the relationship between the use of acetaminophen, ibuprofen, and Topicaine prior to screening mammography and the perception of discomfort during the procedure? 2. What is the relationship between perception of discomfort and overall satisfaction with the mammography experience? 3. What is the relationship between the perception of discomfort and plans for future mammograms? 4. What other factors are associated with the perception of discomfort and satisfaction?

Detailed description

Breast cancer is prevalent, deadly, costly, and has low cure rates unless detected in its early stages. Mammography is the key component to early detection, yet it remains underutilized due to cost, access, and factors such as fear of pain. Multiple studies have shown that most women find mammography uncomfortable, even painful. Yet, little research has been done to find methods to reduce mammography-related discomfort. In an unpublished Master's thesis, this investigator found that women who expected discomfort \> 40 on a visual analog scale (VAS) who were pre-medicated with 1000 mg of acetaminophen reported lower discomfort scores than those pre-medicated with placebo, but the sample size was too small to reach statistical significance. Further study on the effects of pre-medication is needed. Pain should not be associated with a potentially lifesaving procedure. A more comfortable and positive experience with mammography may increase the number of women who participate in regular mammography screening, and, thereby, increase early detection and reduce the mortality rate, costs, and emotional trauma associated with breast cancer.

Interventions

DRUG800 mg ibuprofen
DRUG1 oz 4% lidocaine gel

Sponsors

Mountain States Tumor and Medical Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women scheduled for age-appropriate screening mammography at St. Luke's Breast Cancer Detection Center * Expect discomfort of 40 or greater on a scale of 0-100 * Willing to arrive 1 hour early for appointment to enroll in study

Exclusion criteria

Women who: * expect discomfort from their mammogram to be \< 40 on a scale of 0-100 * cannot understand or read English or who are unable to complete the consent process or questionnaire for reasons such as hearing impairment or other physical or mental disabilities * have a sensitivity or allergy to acetaminophen, ibuprofen, or lidocaine * have significant liver or kidney dysfunction * are breast-feeding * cannot arrive a minimum of 60 minutes earlier than their appointment time * have taken any pain relief medications within 24 hours of their mammogram appointment, including over-the-counter medications.

Design outcomes

Primary

MeasureTime frame
Discomfort scores on a visual analog scale at recruitment, at enrollment, and after mammogram
Satisfaction scores on a visual analog scale after mammogram

Secondary

MeasureTime frame
Pre-mammogram breast tenderness scores on a visual analog scale at enrollment
Pre-mammogram anxiety scores on a visual anxiety scale at enrollment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026